Advertisement
DHR vs RVTY
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Revvity, Inc. (RVTY) Stock Comparison
Key Takeaways
- DHR (Danaher Corporation) operates as a larger-scale diversified life sciences and diagnostics company with three primary segments, while RVTY (Revvity, Inc.) focuses on health sciences solutions with emphasis on diagnostics and life sciences tools following its 2023 rebranding.
- Recent market activity shows both stocks trading in the diagnostics and research sector, with DHR maintaining a market capitalization exceeding $144 billion compared to RVTY’s approximately $12.3 billion.
- Year-to-date performance through mid-July 2026 indicates RVTY advancing about 14% versus DHR’s roughly 10.6%, though both have trailed broader market gains over longer periods in some metrics.
- Upcoming earnings releases—DHR on July 21 and RVTY on August 4—represent near-term catalysts that could influence sentiment in the current environment.
- DHR has pursued tuck-in acquisitions such as StatLab Medical Products, while RVTY has highlighted technology integrations including AI enhancements to its Signals platform.
- Valuation multiples differ notably, with DHR showing a trailing P/E around 39.5 and RVTY near 53, reflecting varying growth expectations and scale advantages.
Introduction
Investors and traders comparing DHR and RVTY often seek insight into two healthcare-focused companies operating within the diagnostics and research industry. Both firms provide tools and technologies that support scientific discovery, biopharmaceutical development, and clinical diagnostics, making them relevant for those monitoring life sciences exposure. This comparison highlights differences in scale, recent performance trends, and positioning that may appeal to portfolio managers evaluating sector allocation or relative value opportunities in the current market environment.
DHR Overview and Recent Performance
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services across biotechnology, life sciences, and diagnostics segments. In recent weeks, DHR shares have shown resilience amid broader sector movements, closing near $203.83 as of July 17, 2026. The stock has posted a year-to-date gain of approximately 10.59%, outpacing the S&P 500’s 8.94% advance over the same period. Sentiment has been supported by ongoing acquisition activity, including the StatLab Medical Products deal aimed at expanding diagnostics capabilities, alongside anticipation surrounding its July 21 earnings report where analysts project modest revenue growth.
RVTY Overview and Recent Performance
Revvity, Inc. provides health sciences solutions, technologies, and services focused on instruments, reagents, software, and detection platforms for diagnostics and life sciences applications. Formerly PerkinElmer, the company rebranded in 2023. In recent market activity, RVTY shares closed at $110.15 on July 17, 2026, reflecting a year-to-date increase of about 14.08%. Performance has benefited from technology updates, including AI integrations, while the company prepares for its August 4 earnings release. The smaller scale relative to peers has contributed to distinct volatility patterns compared with larger sector participants during recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and performance statistics, with many showing win rates ranging from 60% to over 80% in backtested or live scenarios depending on the specific model and ticker focus. Users can review detailed metrics such as profit factors, drawdowns, and trade frequency to identify suitable options. Explore the full curated list on the Trending AI Robots page for additional insights.
Head-to-Head Comparison
DHR and RVTY both serve the diagnostics and research space yet differ markedly in scale and business breadth. Danaher’s diversified model across biotechnology, life sciences, and diagnostics provides broader exposure and acquisition-driven growth levers, whereas Revvity concentrates on specialized workflows in diagnostics and life sciences following its rebranding. Recent momentum has favored RVTY on a year-to-date basis, while DHR offers greater stability through its larger market capitalization and established track record. Risk factors include execution on acquisitions for DHR and organic growth variability plus regulatory considerations for RVTY. Sector sentiment remains tied to healthcare innovation spending, with both names sensitive to macroeconomic influences on research and development budgets. Valuation contrasts highlight DHR’s more moderate multiples against RVTY’s premium forward expectations.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance sheet stability, and near-term catalysts, Tickeron’s AI models currently assign a modestly higher probabilistic preference to DHR. Its larger scale and diversified segment exposure may support more resilient positioning amid sector rotations, though RVTY’s recent outperformance and technology initiatives warrant continued monitoring. Outcomes will likely hinge on earnings delivery and broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a Hold and RVTY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileRVTY’s FA Score has 2 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- RVTY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while RVTY’s TA Score has 4 bullish TA indicator(s).
- DHR’s TA Score: 4 bullish, 5 bearish.
- RVTY’s TA Score: 4 bullish, 5 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -6.05% price change this week, while RVTY (@Medical Specialties) price change was +0.29% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
DHR is expected to report earnings on Oct 27, 2026.
RVTY is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| DHR | RVTY | DHR / RVTY | |
| Capitalization | 135B | 12.3B | 1,098% |
| EBITDA | 7.08B | 773M | 916% |
| Gain YTD | -15.994 | 14.411 | -111% |
| P/E Ratio | 34.14 | 53.11 | 64% |
| Revenue | 24.8B | 2.9B | 855% |
| Total Cash | N/A | N/A | - |
| Total Debt | 18.5B | 3.35B | 552% |
DHR | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 80 | 89 | |
PRICE GROWTH RATING 1..100 | 51 | 41 | |
P/E GROWTH RATING 1..100 | 72 | 28 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (6) in the Medical Specialties industry is in the same range as RVTY (15). This means that DHR’s stock grew similarly to RVTY’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RVTY (100). This means that DHR’s stock grew similarly to RVTY’s over the last 12 months.
DHR's SMR Rating (80) in the Medical Specialties industry is in the same range as RVTY (89). This means that DHR’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (41) in the Medical Specialties industry is in the same range as DHR (51). This means that RVTY’s stock grew similarly to DHR’s over the last 12 months.
RVTY's P/E Growth Rating (28) in the Medical Specialties industry is somewhat better than the same rating for DHR (72). This means that RVTY’s stock grew somewhat faster than DHR’s over the last 12 months.
| DHR | RVTY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 46% | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 61% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 70% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 53% | 2 days ago 61% |
| Advances ODDS (%) | 3 days ago 54% | 3 days ago 64% |
| Declines ODDS (%) | 5 days ago 61% | 6 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 57% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 64% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.